NASDAQ:ADMAADMA Biologics Stock Price, Forecast & News

$2.93

+0.07 (+2.45 %)

(As of 06/4/2020 12:52 PM ET)

Add

Compare

Today's Range

$2.90

Now: $2.93▼

$3.06

50-Day Range

$2.42

MA: $2.83▼

$3.29

52-Week Range

$1.45

Now: $2.93▼

$5.48

Volume77,824 shs

Average Volume3.55 million shs

Market Capitalization$253.01 million

P/E RatioN/A

Dividend YieldN/A

Beta2.05

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also offers Nabi-HB, a hyperimmune globulin for the treatment of acute exposure; and Bivigam, an intravenous immune globulin for the treatment of primary humoral immunodeficiency. In addition, it operates source plasma collection facilities in Norcross, Marietta, and Kennesaw, Georgia. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
ADMA Biologics has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.40, ADMA Biologics has a potential upside of 152.6% from its current price of $2.93.
Amount of Analyst Coverage
ADMA Biologics has only been the subject of 3 research reports in the past 90 days.

3.0 Community Rank

Outperform Votes
ADMA Biologics has received 355 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ADMA Biologics has received 237 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
ADMA Biologics has received 59.97% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote “Outperform” if you believe ADMA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
ADMA Biologics does not currently pay a dividend.
Dividend Growth
ADMA Biologics does not have a long track record of dividend growth.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ADMA Biologics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,050,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 15.20% of the stock of ADMA Biologics is held by insiders.
Percentage Held by Institutions
56.12% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for ADMA Biologics are expected to grow in the coming year, from ($0.72) to ($0.28) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ADMA Biologics is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ADMA Biologics is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ADMA Biologics has a P/B Ratio of 6.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.21 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ADMA

Previous Symbol

CUSIPN/A

CIK1368514

Webwww.admabiologics.com

Phone201-478-5552

Debt

Debt-to-Equity Ratio1.02

Current Ratio11.90

Quick Ratio8.14

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$29.35 million

Price / Sales8.62

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.44 per share

Price / Book6.66

Profitability

EPS (Most Recent Fiscal Year)($0.92)

Net Income$-48,280,000.00

Net Margins-151.18%

Return on Equity-105.97%

Return on Assets-35.21%

Miscellaneous

Employees314

Outstanding Shares86,350,000

Market Cap$253.01 million

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive ADMA News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.

ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions

How has ADMA Biologics' stock been impacted by COVID-19 (Coronavirus)?

ADMA Biologics' stock was trading at $2.31 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ADMA stock has increased by 26.8% and is now trading at $2.93. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ADMA Biologics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ADMA Biologics.

When is ADMA Biologics' next earnings date?

ADMA Biologics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for ADMA Biologics.

How were ADMA Biologics' earnings last quarter?

ADMA Biologics Inc (NASDAQ:ADMA) issued its earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.13. The biotechnology company had revenue of $10.20 million for the quarter, compared to analysts' expectations of $10.71 million. ADMA Biologics had a negative net margin of 151.18% and a negative return on equity of 105.97%. View ADMA Biologics' earnings history.

What price target have analysts set for ADMA?

5 brokerages have issued 1-year price targets for ADMA Biologics' stock. Their forecasts range from $4.00 to $12.00. On average, they anticipate ADMA Biologics' share price to reach $7.40 in the next year. This suggests a possible upside of 152.6% from the stock's current price. View analysts' price targets for ADMA Biologics.

Has ADMA Biologics been receiving favorable news coverage?

Media stories about ADMA stock have been trending extremely positive recently, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ADMA Biologics earned a coverage optimism score of 5.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutADMA Biologics.

Who are some of ADMA Biologics' key competitors?

Some companies that are related to ADMA Biologics include Sorrento Therapeutics (SRNE), BAVARIAN NORDIC/S (BVNRY), Orchard Therapeutics (ORTX), Krystal Biotech (KRYS), Cellectis (CLLS), BioCryst Pharmaceuticals (BCRX), Avrobio (AVRO), Nantkwest (NK), Replimune Group (REPL), Aerie Pharmaceuticals (AERI), AVITA MED LTD/S (RCEL), Vericel (VCEL), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY) and Oyster Point Pharma (OYST). View all competitors.

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), Trevena (TRVN), Nokia Oyj (NOK), Matinas BioPharma (MTNB), Chesapeake Energy (CHK), Miragen Therapeutics (MGEN), Tilly's (TLYS), Unum Therapeutics (UMRX) and OrganiGram (OGI).

Who are ADMA Biologics' key executives?

ADMA Biologics' management team includes the following people:

Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 42)
Dr. Jerrold B. Grossman Ph.D., D.P.S., Co-Founder & Vice Chairman (Age 71)
Mr. Brian Lenz CPA, CPA, Exec. VP & CFO (Age 47)
Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 73)
Mr. James Hauert, Sr. VP of Commercialization & Strategy

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by many different institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (19.21%), BlackRock Inc. (6.14%), Sphera Funds Management LTD. (2.13%), Prosight Management LP (1.44%), State Street Corp (1.38%) and Geode Capital Management LLC (1.31%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Biotest Divestiture Trust, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View institutional ownership trends for ADMA Biologics.

Which major investors are selling ADMA Biologics stock?

ADMA stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Morgan Stanley, UBS Group AG, Squarepoint Ops LLC, and Parametric Portfolio Associates LLC. View insider buying and selling activity for ADMA Biologics.

Which major investors are buying ADMA Biologics stock?

ADMA stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, BlackRock Inc., Sphera Funds Management LTD., Prosight Management LP, Franklin Resources Inc., Ikarian Capital LLC, Nuveen Asset Management LLC, and Geode Capital Management LLC. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Life Sciences Maste Perceptive, and Perceptive Advisors Llc. View insider buying and selling activity for ADMA Biologics.

How do I buy shares of ADMA Biologics?

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ADMA Biologics' stock price today?

One share of ADMA stock can currently be purchased for approximately $2.93.

How big of a company is ADMA Biologics?

ADMA Biologics has a market capitalization of $253.01 million and generates $29.35 million in revenue each year. The biotechnology company earns $-48,280,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. ADMA Biologics employs 314 workers across the globe.

What is ADMA Biologics' official website?

The official website for ADMA Biologics is www.admabiologics.com.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff